Abstract
The chimeric peptide M617, galanin(1–13)-Gln14-bradykinin(2–9)amide, is a novel galanin receptor ligand with increased subtype specificity for GalR1 and agonistic activity in cultured cells as well as in vivo. Displacement studies on cell membranes expressing hGalR1 or hGalR2 show the presence of a high affinity binding site for M617 on GalR1 (Ki=0.23±.12 nM) while lower affinity was seen towards GalR2 (Ki=5.71±1.28 nM) resulting in 25-fold specificity for GalR1. Activation of GalR1 upon stimulation with M617 is further confirmed by internalization of a GalR1-EGFP conjugate. Intracellular signaling studies show the ability of M617 to inhibit forskolin stimulated cAMP formation with 57% and to produce a 5-fold increase in inositol phosphate (IP) accumulation. Agonistic effects on signal transduction are shown on both receptors studied after treatment with M617 in the presence of galanin. In noradrenergic locus coeruleus neurons, M617 induces an outward current even in the presence of TTX plus Ca2+, high Mg2+, suggesting a postsynaptic effect. Intracerebroventricular (i.c.v.) administration of M617 dose-dependently stimulates food uptake in rats while, in contrast, M35 completely fails to affect the feeding behavior. Spinal cord flexor reflex is facilitated by intrathecal (i.t.) administration of M617 as well as galanin with no significant change upon pre-treatment with M617. M617 dose dependently antagonizes the spinal cord hyperexcitablility induced by C-fiber conditioning stimulus and does neither enhance nor antagonize the effect of galanin. These data demonstrate a novel galanin receptor ligand with subtype specificity for GalR1 and agonistic activity, both in vitro and in vivo.
Similar content being viewed by others
Abbreviations
- CHO:
-
Chinese Hamster Ovary Cells
- CS:
-
conditional stimulation
- DMF:
-
N,N-dimethylformamide
- GalR1:
-
galanin receptor type 1
- GalR2:
-
galanin receptor type 2
- HM:
-
HEPES-buffered magnesium solution
- i.c.v.:
-
intracerebroventricular
- i.p.:
-
intraperitoneal
- i.t.:
-
intrathecal
- IP:
-
inositol phosphates
- LC:
-
locus coeruleus
- PBS:
-
phosphate-buffered saline
References
U. Abramov A. Florén D. J. Echevarria A. Brewer H. Manuzon J. K. Robinson T. Bartfai E. Vasar Ü. Langel (2004) Neuropeptides 38 55–61
T. Bartfai Ü. Langel K. Bedecs S. Andell T. Land S. Gregersen B. Ahrén P. Girotti S. Consolo R. Corwin et al. (1993) Proc. Natl. Acad. Sci. USA 90 11287–11291
B. Borowsky M. W. Walker L.Y. Huang K. A. Jones K. E. Smith J. Bard T. A. Branchek C. Gerald (1998) Peptides 19 1771–1781
T. A. Branchek K. E. Smith C. Gerald M. W. Walker (2000) Trends Pharmacol. Sci 21 109–117
V. Chan-Palay (1988) Brain Res. Bull 21 465–472
J. L. Ch’ng N. D. Christofides P. Anand S. J. Gibson Y. S. Allen H. C. Su K. Tatemoto J. F. Morrison J. M. Polak S. R. Bloom (1985) Neuroscience 16 343–354
J. N. Crawley (1999) Neuropeptides 33 369–375
J. N. Crawley J. K. Robinson Ü. Langel T. Bartfai (1993) Brain Res 600 268–272
Z. Fathi A. M. Cunningham L. G. Iben P. B. Battaglino S. A. Ward K. A. Nichol K. A. Pine J. Wang M. E. Goldstein T. P. Iismaa I. A. Zimanyi (1997) Brain Res. Mol. Brain Res 51 49–59
A. Florén T. Land Ü. Langel (2000) Neuropeptides 34 331–337
E. Habert-Ortoli B. Amiranoff I. Loquet M. Laburthe J. F. Mayaux (1994) Proc. Natl. Acad. Sci. USA 91 9780–9783
E. Heuillet Z. Bouaiche J. Menager P. Dugay N. Munoz H. Dubois B. Amiranoff A. Crespo J. Lavayre J. C. Blanchard et al. (1994) Eur. J. Pharmacol 269 139–147
A. Ignatov I. Hermans-Borgmeyer H. C. Schaller (2004) Neuropharmacology 46 1114–1120
K. Kask M. Berthold J. Bourne S. Andell Ü. Langel T. Bartfai (1995) Regul. Peptides 59 341–348
S. E. Kyrkouli B. G. Stanley R. D. Seirafi S. F. Leibowitz (1990) Peptides 11 995–1001
H. X. Liu T. Hökfelt (2002) Trends Pharmacol. Sci 23 468–474
H. X. Liu P. Brumovsky R. Schmidt W. Brown K. Payza L. Hodzic C. Pou C. Godbout T. Hökfelt (2001) Proc. Natl. Acad. Sci. USA 98 9960–9964
X. Ma Y. G. Tong R. Schmidt W. Brown K. Payza L. Hodzic C. Pou C. Godbout T. Hökfelt Z. Q. Xu (2001) Brain Res 919 169–174 Occurrence Handle10.1016/S0006-8993(01)03033-5 Occurrence Handle1:CAS:528:DC%2BD3MXnvFCktrk%3D Occurrence Handle11689176
A. Mazarati Ü. Langel T. Bartfai (2001) Neuroscientist 7 506–517 Occurrence Handle1:CAS:528:DC%2BD3MXptFGjsb8%3D Occurrence Handle11765128
T. Melander T. Hökfelt A. Rökaeus A. C. Cuello W. H. Oertel A. Verhofstad M. Goldstein (1986) J. Neurosci 6 3640–3654
A. Ottlecz G. D. Snyder S. M. McCann (1988) Proc. Natl. Acad. Sci. USA 85 9861–9865
A. Sjöholm S. Efendic (2001) Exp. Clin. Endocrinol. Diabetes 109 IssueIDSuppl 2 S109–121
G. Skofitsch D. M. Jacobowitz (1985) Brain Res. Bull 15 191–195
G. Skofitsch D. M. Jacobowitz R. Amann F. Lembeck (1989) Neuroendocrinology 49 419–427
K. E. Smith C. Forray M. W. Walker K. A. Jones J. A. Tamm J. Bard T. A. Branchek D. L. Linemeyer C. Gerald (1997) J. Biol. Chem 272 24612–24616
K. E. Smith M. W. Walker R. Artymyshyn J. Bard B. Borowsky J. A. Tamm W. J. Yao P. J. Vaysse T. A. Branchek C. Gerald K. A. Jones (1998) J. Biol. Chem 273 23321–23326
K. Tatemoto A. Rökaeus H. Jørnvall T. J. McDonald V. Mutt (1983) FEBS Lett. 164 124–128
A. Valkna A. Juréus E. Karelson M. Zilmer T. Bartfai Ü. Langel (1995) Neurosci. Lett 187 75–78
S. Wang T. Hashemi C. He C. Strader M. Bayne (1997a) Mol. Pharmacol 52 337–343
S. Wang C. He T. Hashemi M. Bayne (1997b) J. Biol. Chem 272 31949–31952
S. Wang T. Hashemi S. Fried A. L. Clemmons B. E. Hawes (1998) Biochemistry 37 6711–6717
Z. Wiesenfeld-Hallin M. J. Villar T. Hökfelt (1989) Brain Res. 486 205–213
C. C. Wrenn J. N. Crawley (2001) Prog. Neuropsychopharmacol. Biol. Psychiatry 25 283–299
X. J. Xu Z. Wiesenfeld-Hallin M. J. Villar J. Fahrenkrug T. Hökfelt (1990) Eur. J. Neurosci 2 733–743
X. J. Xu Z. Wiesenfeld-Hallin T. Hökfelt (1991) Brain Res. 541 350–353
X. J. Xu T. Hökfelt T. Bartfai Z. Wiesenfeld-Hallin (2000) Neuropeptides 34 137–147
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lundström, L., Sollenberg, U., Brewer, A. et al. A Galanin Receptor Subtype 1 Specific Agonist. Int J Pept Res Ther 11, 17–27 (2005). https://doi.org/10.1007/s10989-004-1717-z
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10989-004-1717-z